Navigation Links
Simmons Hanly Conroy Shareholder Trent Miracle Appointed Co-Lead in Federal Testosterone Replacement Therapy Litigation
Date:8/5/2014

CHICAGO, Aug. 5, 2014 /PRNewswire/ -- A federal judge has appointed Simmons Hanly Conroy Shareholder Trent Miracle as co-lead counsel in the national multidistrict litigation pending against the manufacturers of testosterone therapy replacement treatments.

In an order entered July 31, the Honorable Matthew F. Kennelly, of the U.S. District Court for the Northern District of Illinois, appointed Miracle and attorneys Ronald E. Johnson Jr. and Christopher A. Seeger as co-lead counsel for the plaintiffs in the testosterone replacement therapy products liability litigation. Miracle and his co-leads will manage the federal litigation and oversee 29 other attorneys representing men who were seriously injured while taking testosterone replacement therapies.

"This is an important litigation that could impact thousands of men throughout the country," Miracle said. "Judge Kennelly's appointments include some of the nation's top trial attorneys, and I'm looking forward to working with them as we fight for the rights of those unnecessarily harmed while receiving testosterone replacement therapy."

Earlier this year, the U.S. Food & Drug Administration issued a safety announcement about the increased risks associated with low testosterone treatment therapies. Based on new research which found men taking testosterone treatments had a greater chance of suffering a heart attack or stroke, the FDA launched its own investigation of testosterone replacement therapy.

In February 2014, Simmons Hanly Conroy, led by Miracle, filed the first low testosterone lawsuits in the country following the FDA's warning. He was subsequently appointed co-chair of the American Association for Justice's Testosterone Therapy Litigation Group.

The testosterone replacement therapy MDL will help men injured by testosterone treatments receive justice in a timely manner, Miracle said.

"Low testosterone treatments like AndroGel have been heavily marketed to consumers without regard for the possible risks they could cause," Miracle said. "These men looked to testosterone treatments to help them maintain their quality of life and instead were seriously injured."

Simmons Hanly Conroy and its attorneys have held multiple national positions of note in pharmaceutical mass torts litigations. Federal judges have appointed the firm's attorneys to serve on multiple plaintiff steering committees in mass tort litigations including Yaz, DePuy hip implants, Propecia, Transvaginal Mesh Litigation, Lipitor, and more. Their work has resulted in millions of dollars secured on behalf of clients injured by dangerous drugs and defective medical devices.

"My clients can rest assured that they have a national team of skilled trial attorneys working on their behalf to ensure they receive justice," Miracle said.

The case is In Re: Testosterone Replacement Therapy Products Liability Litigation, MDL No. 2545, Case No. 14 C 1748.

About Simmons Hanly Conroy Pharmaceutical Division
SIMMONS HANLY CONROY LLC is a leading national law firm in pharmaceutical litigation. The firm has extensive experience litigating complex medical matters and its attorneys have held leadership roles in cases of national scope on behalf of individuals who have been injured by dangerous drugs or defective medical devices. The firm has recovered more than half a billion dollars in verdicts and settlements in cases involving Bextra, Oxycontin, Vioxx, Yaz and more. Learn more at www.simmonspharmalaw.com.

Contact: Mark Motley, Chief Marketing Officer
618.259.2222 | mmotley@simmonsfirm.com


'/>"/>
SOURCE Simmons Hanly Conroy
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Positron Appoints Charles Conroy As Chief Operating Officer
2. TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card
3. Sinovac Schedules 2014 Annual Meeting of Shareholders
4. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
5. Medbox Updates Shareholders on Dividend Issuance
6. Mindray Announced Shareholder Resolutions Post 2013 Annual General Meeting
7. Simcere Pharmaceutical Group Announces Shareholders Approval of the Merger Agreement
8. Pro-Dex, Inc. Announces Plans For Rights Offering To Shareholders
9. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims That the Merger May Not Be in the Best Interest of Investors of Solta Medical, Inc. - SLTM
10. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
11. Concord Medical Announces the Closing of Acquisition of Its Shares by CEO and COO from Other Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... to 2023" report to their offering. ... The ablation device global market is ... million by 2023. Ablation is the minimally invasive ... from cancerous or diseased tissue removal, to the removal of abnormally ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold 300 ... Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while ... HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, Lower ...
(Date:3/29/2017)... ... 29, 2017 , ... Dr. Angela Cotey, a noted general dentist in Mt. ... patients, with or without a referral. Dr. Cotey knows that interceptive orthodontics ... experience. When patients receive early treatment, they may achieve straight teeth with less treatment ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Curio Wellness ... to announce the finalization of the company’s executive management team with prominent executives from ... operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one ... cancers and is touted to be the next revolution in our fight against this ... in the form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , ...
(Date:3/29/2017)... Philadelphia, PA (PRWEB) , ... March 29, 2017 , ... ... Moelis, W’80, WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift ... a deferred admission opportunity that will provide a pathway to a Wharton MBA for ...
Breaking Medicine News(10 mins):